ICCM — Icecure Medical Share News
0.000.00%
Last trade - 00:00- $3.56m
- -$8.47m
- $3.38m
IceCure up after FDA panel backs use of its breast cancer treatment system
Brief: FDA Advisory Panel Backs Icecure's Prosense Cryoablation For Early-Stage Low Risk Breast Cancer
Brief: Icecure Receives Notice Of Allowance From U.S. Patent And Trademark Office For Its Next-Generation Cryoablation System
Brief: IceCure Medical Says FDA Advisory Panel Meeting Date For Marketing Authorization Of ProSense Scheduled For Nov 7
Brief: Icecure Medical Uspto Grants Notice Of Allowance For Additional Patent
Brief: IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
Brief: European Study Provides More Evidence Supporting Icecure's Prosense® Is Safe & Effective Cryoablation Treatment For Metastatic And Recurrent Breast Cancer
Brief: US Food And Drug Administration Grants Regulatory Clearance To IceCure For Next-Gen XSense Cryoablation System With CryoProbes
Brief: Positive Data From Icecure's Kidney Cancer Clinical Study Presented At Interventional Radiology Conference
Brief: FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense
Brief: Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally
Brief: IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results
Brief: IceCure Submits FDA Regulatory Filing For New XSense Cryoablation System With Cryoprobes
Brief: Icecure Receives Notice Of Patent Allowance In Japan For A Novel Cryogen Flow Control To Optimize Patient Outcomes
U.S. STOCKS ON THE MOVE-TPG, R1 RCM, Zoom
U.S. STOCKS ON THE MOVE-Micron, Krystal Biotech, Pilgrim's Pride
U.S. STOCKS ON THE MOVE-Domino's Pizza, Voyager, Freshpet
IceCure gains on positive results from study in cancer patients
IceCure rises on FDA's positive response for De Novo review request